Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 3.5% – Still a Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price rose 3.5% on Thursday . The stock traded as high as $124.66 and last traded at $122.10. Approximately 370,039 shares were traded during mid-day trading, a decline of 71% from the average daily volume of 1,267,738 shares. The stock had previously closed at $117.99.

Analyst Ratings Changes

SRPT has been the subject of several analyst reports. Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Bank of America lifted their price objective on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. Robert W. Baird lifted their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, June 21st. Royal Bank of Canada lifted their price objective on shares of Sarepta Therapeutics from $181.00 to $182.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $165.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 21st. Two research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $185.47.

Sarepta Therapeutics Price Performance

The firm has a market capitalization of $11.77 billion, a price-to-earnings ratio of 1,131.91 and a beta of 0.82. The business’s fifty day simple moving average is $130.19 and its 200 day simple moving average is $132.46. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same period last year, the firm earned ($0.27) earnings per share. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. On average, research analysts forecast that Sarepta Therapeutics, Inc. will post 1.45 EPS for the current year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently made changes to their positions in the business. Mather Group LLC. purchased a new stake in shares of Sarepta Therapeutics in the 1st quarter worth about $28,000. Riggs Asset Managment Co. Inc. grew its holdings in Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares in the last quarter. Innealta Capital LLC purchased a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $31,000. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics in the first quarter valued at $32,000. Finally, GAMMA Investing LLC grew its holdings in shares of Sarepta Therapeutics by 37.0% in the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.